Music |
Video |
Movies |
Chart |
Show |
Developing treatments for indolent non hodgkin lymphoma (ecancer) View |
Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma (ecancer) View |
Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma (ecancer) View |
Dose escalation of CPI-613 with bendamustine for relapsed T Cell NHL (ecancer) View |
obinutuzumab plus bendamustine in rituximab-refractory indolent non-Hodgkin lymphoma (Oncoletter) View |
Lymphoma and Bendamustine with Dr Pierre Laneuville (LymphomaCanada) View |
Novel ADC for relapsed/refractory lymphoma (ecancer) View |
Chemotherapy-free treatment of indolent lymphomas (Lymphoma Hub) View |
Bendamustine for indolent lymphoma reduces relapse after 10 years (ecancer) View |
FL: Switching to Bendamustine/Rituximab at Progression (Targeted Oncology) View |